

Veteran Issue Updates July 2009
These Awards Are Presented To Sites of Veteran Awareness.... To receive One
Please Submit A Site
Celebrating 12th Year Serving Veterans
Agent Orange Update
| Agent Orange Updates Veteran Issue Updates July 2009 This Week in the Pentagon Video Gulf War Syndrome Gulf War Bulletin Board Editorial |
Agent Orange
Health Topics: Cancer
Content provided by: Agent Orange Exposure Tied to Prostate Cancer Return
Study finds vets at higher risk of aggressive recurrence only 8 months after surgery--
Update #1.
Robert Preidt
THURSDAY, April 23, 09 (Health Day News) --
U.S. male military veterans exposed to the Agent Orange herbicide/defoliant are at increased risk for aggressive recurrence of prostate cancer, a new study finds.
It included 1,495 veterans who'd had surgery to remove cancerous prostates. Of those, the 206 men who'd been exposed to Agent Orange were nearly 50 percent more likely to develop an aggressive recurrence of their cancer, even though their disease seemed relatively non-aggressive at the time of surgery.
The study also found it took only eight months for prostate specific antigen (PSA) levels -- an indicator of cancer aggressiveness -- to double among the Agent Orange-exposed veterans with recurrent cancer, compared to more than 18 months among non-exposed veterans.
The study is published in the May issue of the British Journal of Urology International.
"There is something about the biology of these cancers that are associated with prior Agent Orange exposure that is causing them to be more aggressive.
We need to get the word out," study corresponding author Dr. Martha Terris, chief of urology at the Charlie Norwood VA Medical Center in Augusta and professor of urology at the Medical College of Georgia School of Medicine, said in a school news release.
She said doctors treating prostate cancer patients who've been exposed to Agent Orange need to be aware that these patients may require closer monitoring and so-called salvage therapy quickly if their prostate cancer returns.
"Not only are their recurrence rates higher, but their cancers are coming back and growing much faster when they do come back," Terris said.
There's increasing evidence that exposure to Agent Orange, which was used during the Vietnam War, increases the risk for a number of health problems. Agent Orange contained a known carcinogen called dioxin, which is also found in herbicides and pesticides used by U.S. farmers, according to background information in the news release about the study.
More information: The American Cancer Society has more about prostate cancer.
SOURCE: Medical College of Georgia, news release, April 20, 2009.
Update #2
July, 09
The Department of Veterans Affairs has added Al amyloidosis to the list of presumptive service-connected disease associated with the exposure to certain herbicide agents, including Agent Orange. A recent Institute of Medicine report on Agent Orange found a positive association between the disease and exposure to herbicides used in the Vietnam War. As a result, the VA has amended regulations to grant presumptive service -connection. The rule also applies to previously denied claims of AL armyloidosis submitted by Vietnam veterans. AL armyloidosis is a rate plasma cell disorder which originates in bone marrow and is usually treated with chemotherapy. Is is the most common type of armydoidosis in the U.S.,with an estimated 2,000 cases diagnosed each year. The disease results when protein build up in one or more organs causes malfunction. The heart, kidneys, nervous system and gastrointestinal tract are most often affected. Although AL armyloisdosis is not cancer, it is very serious and disabling or life-threatening. It joins the list of 11 other presumptively service-connection conditions recognized in Vietnam veterans. They include choracne; Non-Hodgkin's lymphoma; soft tissue sarcoma (other than osteosarcoma,chondrosarcoma, Kaposi's sarcoma, or mesotheloma); Hodgkin's disease; porphyria cutanea tarda; multiple myeloma; respiratory cancers, including cancers of tghe lung, larynx, trachea, and bronchus; prostate cancer; acute and subacute transient peripheral neuopathy; Type 2 diabetes; and chronic lymphocystic leukemia.
For additional information, please contact
your nearest National Service Office.